Parabilis Medicines priced a $670 million upsized initial public offering on Nasdaq, extending what has become a steady run of large biopharma debuts in 2026. The company offered 3.5 million shares at $20, after an expansion that could push gross proceeds to $770 million if underwriters fully exercise options. Parabilis is developing oncology programs led by zolucatetide (FOG-001) across multiple solid tumor settings and is set to fund additional trials and pipeline buildout using the IPO proceeds. The listing follows recent large offerings in biotech, reflecting continuing investor appetite for late-stage momentum and clear clinical pathways. The IPO also underlines how “scale” capital is flowing toward well-capitalized cancer developers rather than across the entire sector. In parallel, market observers noted that enthusiasm remains selective, with credit for strong backing and institutional support. For the industry, Parabilis’ debut is another datapoint that large-format public financing is back—at least for franchises with credible assets and defined development plans.